Solid Tumor Therapeutics Program
Program Co-Leaders: Lee Ratner, MD, PhD, and Barry P. Sleckman, MD, PhD
The Solid Tumor Therapeutics Program of the Siteman Cancer Center consists of 42 members representing multiple departments across the Washington University School of Medicine campus. The goal of the program is to bring new insights from Siteman's basic science “omics” programs into innovative clinical trials that will have an important impact on improving oncologic care for patients. Collaborations with the other Siteman Cancer Center programs are fostered and have resulted in grants, publications and clinical projects
The Solid Tumor Therapeutics Program provides the supporting network for an expanding Developmental Therapeutics program focused on institutional phase 0, I and II studies. Investigators are also integrally involved in research aimed at translating their studies to the clinic in several ways including the identification of small molecule inhibitors of novel DNA damage response pathways that illuminate the causes of cancer or have potential uses in treatment.
The program also supports disease-based working groups to develop, review, prioritize and conduct clinical trials research, with special emphasis on working groups in lung, endometrial, prostate and GI cancer as well as neuro-oncology. Furthermore, the program provides training of investigators at all levels of experience and offers educational opportunities, including seminars, courses, retreats, journal clubs, workshops and work-in-progress meetings.